Table 1. Baseline characteristics in 499 patients with solid or hematological neoplasms undergoing chemotherapy and/or chest radiotherapy.
HF, heart failure; PAD, peripheral arterial disease; AAA, abdominal aortic aneurysm
| Characteristic | Total patients n=499 | Cardiotoxicity risk | ||||
| Very high risk n (%) 220/499 (44.1) | High risk n (%) 61/499 (12.2) | Intermediate risk n (%) 70/499 (14) | Low risk n (%) 113/499 (22.6) | Very low risk n (%) 35/499 (7) | ||
| Age (years) | ||||||
| Median (minimum-maximum value) | 58 (18-97) | 57 (18-88) | 59 (24-85) | 67 (24-97) | 60 (18-88) | 47 (19-64) |
| Female sex n (%) | 289/499 (58) | 146/289 (50.5) | 41/289 (14.1) | 35/289 (12.1) | 67/289 (23.1) | 0/289 (0) |
| Medical history n (%) | ||||||
| Hypertension | 166/499 (33) | 77/166 (46.3) | 19/166 (11.4) | 37/166 (22.2) | 33/166 (19.8) | 0/166 (0) |
| Smoker | 125/499 (25) | 42/125 (33.6) | 10/125 (0.8) | 24/125 (19.2) | 38/125 (30.4) | 11/125 (8.8) |
| Dyslipidemia | 80/499 (16) | 42/80 (52.5) | 7/80 (8.75) | 13/80 (16.25) | 18/80 (22.5) | 0/80 (0) |
| Hypothyroidism | 69/499 (13.8) | 29/69 (42) | 9/69 (13) | 12/69 (17.3) | 18/69 (26) | 1/69 (1.4) |
| Diabetes mellitus 2 | 63/499 (12.6) | 32/63 (50.7) | 7/63 (11.1) | 16/63 (25.3) | 8/63 (12.6) | 0/63 (0) |
| Chronic kidney disease | 24/499 (4.8) | 13/24 (54.1) | 4/24 (16.6) | 1/24 (4.1) | 5/24 (20.8) | 1/24 (4.1) |
| Alcoholism | 22/499 (4.4) | 4/22 (18.2) | 1/22 (4.5) | 9/22 (40.9) | 7/22 (31.8) | 1/22 (4.5) |
| Cancer | 21/499 (4.2) | 11/21 (52.3) | 1/21 (4.7) | 3/21 (14.2) | 6/21 (28.5) | 0/21 (0) |
| Coronary artery disease/PAD/AAA | 20/499 (4) | 9/20 (45) | 1/20 (5) | 9/20 (45) | 1/20 (5) | 0/20 (0) |
| Atrial fibrillation | 12/499 (2.4) | 8/12 (66.6) | 1/12 (8.3) | 1/12 (8.3) | 2/12 (16.6) | 0/12 (0) |
| Obesity | 12/499 (2.4) | 10/12 (83.3) | 1/12 (8.3) | 0/12 (0) | 1/12 (8.3) | 0/12 (0) |
| Heart failure preserved ejection fraction (>40%) | 7/499 (1.4) | 4/7 (57.1) | 2/7 (28.5) | 0/7 (0) | 1/7 (14.2) | 0/7 (0) |
| Previous radiotherapy | 6/499 (1.2) | 3/6 (50) | 0/6 (0) | 2/6 (33.3) | 1/6 (16.6) | 0/6 (0) |
| Stroke | 5/499 (1) | 4/5 (80) | 0/5 (0) | 1/5 (20) | 0/5 (0) | 0/5 (0) |
| Previous use of anthracyclines | 3/499 (0.6) | 2/3 (66.6) | 0/3 (0) | 1/3 (33.3) | 0/3 (0) | 0/3 (0) |
| HF reduced ejection fraction (<40%) | 3/499 (0.6) | 3/3 (100) | 0/3 (0) | 0/3 (0) | 0/3 (0) | 0/3 (0) |
| Valvulopathies | 2/499 (0.4) | 2/2 (100) | 0/2 (0) | 0/2 (0) | 0/2 (0) | 0/2 (0) |